Liver News and Research

RSS

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.

21 Oct 2014

UNMC researcher receives $3.3 million grant to study rare diseases that affect children

University of Nebraska Medical Center researcher, William Rizzo, M.D., has received a five-year, $3.3 million grant to study 10 rare diseases that affect children beginning in infancy or early childhood and throughout their life.

20 Oct 2014

Excess consumption of common pain relievers poses significant health risks to Australians

On the final day of Be Medicinewise Week 2014, NPS MedicineWise is reminding people that excess consumption of common pain relievers is a serious medicine safety issue.

20 Oct 2014

Newly developed agent filters out toxins from body in the event of overdose

Every minute counts in the event of an overdose. ETH professor Jean-Christophe Leroux and his team have developed an agent to filter out toxins from the body more quickly and efficiently.

17 Oct 2014

New oral biologic medication successfully treats precancerous intestinal inflammation

An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of Medicine and Biomedical Sciences.

16 Oct 2014

MGH, MIT partner to accelerate development of diagnostic tools and therapies

A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.

16 Oct 2014

Intake of arsenic linked to cardiovascular disease, diabetes

Associated with various types of cancer such as skin and liver, the intake of arsenic it is also linked to cardiovascular disease and diabetes. According to a long-term research conducted by experts from the Center for Research and Advanced Studies it was determined that this metalloid inhibits enzymes associated with antioxidant protection.

16 Oct 2014

SIRT6 protein inhibits liver and colon cancers, but promotes skin cancer caused by ultraviolet light

A new study published in Cancer Research shows SIRT6—a protein known to inhibit the growth of liver and colon cancers—can promote the development of skin cancers by turning on an enzyme that increases inflammation, proliferation and survival of sun-damaged skin cells.

16 Oct 2014

Researchers discover new kind of stem cell that may hold clues to origins of liver cancer

A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports. The existence of such a cell type contradicts current theory on how organs arise from cell layers in the embryo, and may hold clues to origins of, and future treatment for, liver cancer.

15 Oct 2014

Inflammation in tissue creates a niche for cancer cells

In order to invade healthy tissue, tumor cells must leave the actual tumor and enter the bloodstream or lymphatic system. For this purpose, they use certain enzymes, proteases that break down the tissue surrounding the tumor, thus opening the way for tumor cells to reach blood or lymphatic vessels. To keep the proteases in check, the body produces inhibitors such as the protein TIMP-1, which thwart the proteases in their work.

15 Oct 2014

Obesity greatly accelerates aging of the liver

Using a recently developed biomarker of aging known as an epigenetic clock, UCLA researchers working closely with a German team of investigators have found for the first time that obesity greatly accelerates aging of the liver. This finding could explain the early onset of many age-related diseases, including liver cancer, in obese subjects

13 Oct 2014

TSRI research points toward new method for treating atherosclerosis

Scientists at The Scripps Research Institute have created a synthetic molecule that mimics "good" cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks.

10 Oct 2014

Columbia University's imaging software gets FDA 510k clearance

Columbia University's imaging software that facilitates 3-D lung tumor segmentation, licensed to Varian Medical Systems, has been incorporated into the Smart Segmentation module of Varian's Eclipse treatment planning system and has received FDA 510k clearance.

10 Oct 2014

Decaffeinated coffee may benefit liver health

Researchers from the National Cancer Institute report that decaffeinated coffee drinking may benefit liver health. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that higher coffee consumption, regardless of caffeine content, was linked to lower levels of abnormal liver enzymes. This suggests that chemical compounds in coffee other than caffeine may help protect the liver.

10 Oct 2014

Discovery could lead to treatments for alcohol-related liver diseases

Researchers at the University of Missouri School of Medicine have identified epigenetic protein changes caused by binge drinking, a discovery that could lead to treatments for alcohol-related liver diseases.

9 Oct 2014

New version of Belmont Rapid Infuser to be introduced at ASA 2014

Belmont Instrument Corporation, the widely recognized provider of blood and fluid infusers, will be introducing the new version of The Belmont Rapid Infuser, the RI-2 at the American Society of Anesthesiologists Meeting this week in New Orleans, LA.

8 Oct 2014

State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

Because of its high cost, some state Medicaid programs and prison systems are refusing to provide Sovaldi to any but the sickest patients. Most recently, Oregon last month threatened to limit access to the drug unless it can get Sovaldi at a deeply discounted price. But Sovaldi is only the beginning. Expensive new treatments for certain cancers, rheumatoid arthritis and other conditions also have rattled Medicaid officials, patients and health care providers. What can states do to hold down drug costs? Drug pricing is a complicated and opaque process.

8 Oct 2014

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech.

7 Oct 2014

Lund University researchers identify mechanisms that play vital role in development of type 2 diabetes

By studying identical twins, researchers from Lund University in Sweden have identified mechanisms that could be behind the development of type 2 diabetes. This may explain cases where one identical twin develops type 2 diabetes while the other remains healthy.

7 Oct 2014

Liver News and Research

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Obeticholic acid drug shows promise against bile acid diarrhoea

UNMC researcher receives $3.3 million grant to study rare diseases that affect children

Excess consumption of common pain relievers poses significant health risks to Australians

Newly developed agent filters out toxins from body in the event of overdose

New oral biologic medication successfully treats precancerous intestinal inflammation

MGH, MIT partner to accelerate development of diagnostic tools and therapies

Intake of arsenic linked to cardiovascular disease, diabetes

SIRT6 protein inhibits liver and colon cancers, but promotes skin cancer caused by ultraviolet light

Researchers discover new kind of stem cell that may hold clues to origins of liver cancer

Inflammation in tissue creates a niche for cancer cells

Obesity greatly accelerates aging of the liver

TSRI research points toward new method for treating atherosclerosis

Columbia University's imaging software gets FDA 510k clearance

Decaffeinated coffee may benefit liver health

Discovery could lead to treatments for alcohol-related liver diseases

New version of Belmont Rapid Infuser to be introduced at ASA 2014

State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Lund University researchers identify mechanisms that play vital role in development of type 2 diabetes

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News